Realbotix Issues Financial Reporting Update

Realbotix Corp. provides update on the status and timing of its financial reporting and regulatory filings.

Realbotix Corp ,a leader in AI-powered humanoid robotics, has issued a comprehensive financial reporting update in connection with its ongoing management cease trade order (MCTO) and delayed regulatory filings. The update provides clarity for investors and stakeholders regarding the company’s compliance status, expected filing timelines, and continued operational focus as it works toward resolving the temporary default.

Below is a detailed overview of the situation, what it means for shareholders, and how Realbotix is navigating the process.

Understanding the Management Cease Trade Order (MCTO)

On January 30, 2026, the Ontario Securities Commission (OSC) granted a management cease trade order to Realbotix. The MCTO was issued following a delay in the filing of the company’s audited annual financial statements for the fiscal year ended September 30, 2025.

These filings—collectively referred to as the “2025 Annual Filings”—include:

Audited annual financial statements
Management’s Discussion and Analysis (MD&A)
CEO and CFO certifications

The order was granted under the provisions of National Policy 12-203, which governs Management Cease Trade Orders in Canada.

Importantly, an MCTO is not the same as a full cease trade order. Instead of halting trading in the company’s securities entirely, an MCTO restricts only certain insiders—specifically, the Chief Executive Officer and Chief Financial Officer—from trading in the company’s securities until the required filings are completed and the order is lifted.

This means that:

Public shareholders can continue to trade Realbotix shares.
The trading restriction applies solely to specific members of management.
The order is temporary and conditional upon filing completion.

By issuing an MCTO rather than a general cease trade order, the OSC allows market activity to continue while ensuring accountability at the executive level.

Current Status of the Default

Realbotix has confirmed that since the original MCTO announcement:

There have been no material changes to the information previously disclosed that would reasonably be expected to impact investors.
The company has not defaulted on any other requirements under National Policy 12-203.
It is complying with the alternative information guidelines required under the policy.
No additional undisclosed material information exists, except for a previously announced transaction dated February 12, 2026.

That February 12 release related to a definitive agreement governing the sale of a non-core subsidiary to Onconetix, Inc.. The company clarified that aside from this transaction, there have been no material developments that remain undisclosed.

This transparency is critical. When companies are in default for filing delays, regulators require enhanced disclosure to protect investors and maintain market integrity. Realbotix has stated that it will continue issuing bi-weekly default status reports until all required filings are submitted.

Expected Filing Timeline

Realbotix has outlined revised timelines for completing its regulatory obligations:

The 2025 Annual Filings are expected to be filed on or before March 6, 2026.
The unaudited interim financial statements for the three months ended December 31, 2025 (the “Q1 Interim Filings”) are expected to be filed on or before March 9, 2026.

The Q1 Interim Filings will include:

Unaudited interim financial statements
Interim MD&A
CEO and CFO certifications

Together, the Annual and Q1 Interim Filings are referred to as the “Required Filings.”

Until these documents are submitted, the company will remain subject to the alternative information guidelines under National Policy 12-203. This framework ensures that investors continue receiving updates during the period of default.

Insider Trading Blackout

In addition to the formal MCTO restrictions on the CEO and CFO, Realbotix’s management and other insiders are subject to a broader trading blackout. This blackout reflects principles contained in Section 9 of National Policy 11-207, which addresses Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

The blackout remains in effect until all Required Filings are completed.

This layered compliance structure demonstrates the regulatory safeguards in place:

Executive trading restrictions under the MCTO
Broader insider blackout reflecting national policy guidelines
Ongoing disclosure obligations via bi-weekly updates

For public investors, the key takeaway is that trading in Realbotix shares continues uninterrupted, while insiders face strict restrictions.

Why Filing Delays Happen

Delays in audited financial filings can occur for several reasons, including:

Extended audit procedures
Complex revenue recognition reviews
Internal control documentation issues
Resource constraints
Timing challenges in consolidating subsidiaries

In high-growth technology companies—particularly those operating in emerging industries such as AI-powered robotics—financial reporting can involve added complexity. Intellectual property valuation, R&D capitalization policies, hardware inventory management, and international operations can all contribute to extended audit timelines.

While Realbotix has not publicly detailed the specific cause of the delay, it has emphasized that there have been no material undisclosed issues and that it continues working diligently to finalize the filings.

Business Operations Continue

Despite the temporary regulatory delay, Realbotix’s core operations continue.

The company designs and manufactures AI-powered intelligent humanoid robots for:

Entertainment
Customer service
Companionship

Manufactured in the United States, Realbotix’s robots integrate patented artificial intelligence and robotics technologies to enable:

Lifelike facial expressions
Natural body motion
Computer vision capabilities
Social engagement functionality

The company positions itself as a category leader in the rapidly evolving field of human-centric robotics, where AI intersects with physical embodiment.

Humanoid robotics represents one of the most dynamic frontiers in artificial intelligence. Unlike purely digital AI systems, humanoid robots interact with physical environments and human users in real-world settings. This adds engineering complexity but also opens high-impact commercial opportunities across hospitality, healthcare support, retail, and personal companionship markets.

Investor Considerations

For investors evaluating this development, several factors are worth noting:

1. Scope of the Order

The MCTO is limited in scope and does not prevent public trading.

2. Regulatory Compliance

The company is following prescribed alternative information guidelines and issuing regular updates.

3. Defined Timeline

Clear filing deadlines have been communicated.

4. No Additional Defaults

Realbotix has confirmed there are no other compliance breaches under National Policy 12-203.

5. Continued Operations

There is no indication that the delay impacts the company’s operational capabilities or strategic direction.

Market perception often depends less on the existence of a delay and more on how transparently and efficiently management addresses it. By maintaining disclosure discipline and setting concrete filing targets, Realbotix aims to preserve investor confidence.

The Broader Context: AI and Humanoid Robotics

Realbotix operates within a sector experiencing accelerating innovation and capital interest. Advances in:

Generative AI
Machine vision
Edge computing
Actuation systems
Natural language processing

have made socially interactive humanoid robots increasingly viable.

As demand grows for embodied AI applications—robots capable of interacting naturally with humans—the regulatory and financial stability of companies in this space becomes even more important. Investors are increasingly scrutinizing governance, reporting discipline, and transparency in emerging technology firms.

The timely completion of audited financial statements plays a central role in maintaining credibility within public capital markets.